| Species |
Human |
| Protein Construction |
Neuropilin-1 (Phe22-Lys644)_x000D_
Accession # NP_001019799.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165, No Tag at 5μg/ml (100μl/well) on the plate can bind Neuropilin-1, His, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
70.97 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Neuropilin 1 (NRP1) is a transmembrane glycoprotein that acts as a co-receptor for a number of extracellular ligands including class III/IV semaphorins, certain isoforms of vascular endothelial growth factor and transforming growth factor beta. |
| Synonyms |
BDCA4; NP1; Neuropilin-1; NRP1; CD304; VEGF165R; Neuropilin 1; NRP; Transmembrane Receptor; CD304 Antigen |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
